Iambic Therapeutics closed an oversubscribed financing of over $100 million, backed by investors including ARK, Regeneron Ventures and Illumina Ventures to accelerate its pipeline of AI‑discovered drug candidates. Management said proceeds will fund clinical development and platform expansion, and highlighted recent collaborations — including combo studies with Jazz Therapeutics — that leverage Iambic’s AI models for target prediction and structure‑guided design.